Kyte Pharmaceuticals Downgrade – Company is overvalued

The company’s current market cap is hugely overvalued.  At $17M in revenue and and -101M in net income, this is a completely unproven company and an extremely risky investment. The company’s technological basis is murky and not clear and its management team consists of spotty leadership that attended online schools.

We are rating this stock an F and predicting it will lose at least 75% in value over the next 12 months.


Powered by Facebook Comments